Anandamide membrane transport inhibitor (IC50
= 14 μ
M) that is relatively metabolically stable. Displays some affinity for CB2
receptors but has only weak affinity for CB1
receptors and has no activity at VR1 receptors or FAAH. Anticonvulsive in vivo
following systemic administration.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Bisogno et al.
Anticonvulsant effects of the (-) and (+)isomers of cannabidiol and their dimethylheptyl homologs.
Leite et al.